1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Axial Spondyloarthritis Global Clinical Trials Review, H2, 2016

Axial Spondyloarthritis Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Axial Spondyloarthritis Global Clinical Trials Review, H2, 2016" provides an overview of Axial Spondyloarthritis clinical trials scenario. This report provides top line data relating to the clinical trials on Axial Spondyloarthritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Axial Spondyloarthritis Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Axial Spondyloarthritis to Musculoskeletal Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Axial Spondyloarthritis to Musculoskeletal Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Axial Spondyloarthritis Therapeutics Clinical Trials 28
Prominent Drugs 29
Clinical Trial Profile Snapshots 30
Appendix 73
Abbreviations 73
Definitions 73
Research Methodology 74
Secondary Research 74
About GlobalData 75
Contact Us 75
Disclaimer 75
Source 76

List of Tables
Axial Spondyloarthritis Therapeutics, Global, Clinical Trials by Region, 2016* 6
Axial Spondyloarthritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Axial Spondyloarthritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Axial Spondyloarthritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Axial Spondyloarthritis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Axial Spondyloarthritis Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Axial Spondyloarthritis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
Axial Spondyloarthritis Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14
Proportion of Axial Spondyloarthritis to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2016* 15
Axial Spondyloarthritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Axial Spondyloarthritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Axial Spondyloarthritis to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2016* 18
Axial Spondyloarthritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Axial Spondyloarthritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Axial Spondyloarthritis Therapeutics, Global, Clinical Trials by Phase, 2016* 21
Axial Spondyloarthritis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
Axial Spondyloarthritis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Axial Spondyloarthritis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Axial Spondyloarthritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Axial Spondyloarthritis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
Axial Spondyloarthritis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Axial Spondyloarthritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Axial Spondyloarthritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Axial Spondyloarthritis Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Axial Spondyloarthritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Axial Spondyloarthritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Axial Spondyloarthritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Axial Spondyloarthritis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Axial Spondyloarthritis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Axial Spondyloarthritis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14
Proportion of Axial Spondyloarthritis to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2016* 15
Axial Spondyloarthritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Axial Spondyloarthritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Axial Spondyloarthritis to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2016* 18
Axial Spondyloarthritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Axial Spondyloarthritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Axial Spondyloarthritis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
Axial Spondyloarthritis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
Axial Spondyloarthritis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Axial Spondyloarthritis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Axial Spondyloarthritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Axial Spondyloarthritis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
Axial Spondyloarthritis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Axial Spondyloarthritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Axial Spondyloarthritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 74

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2013 - 2024

Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2013 - 2024

  • $ 4950
  • Industry report
  • November 2016
  • by Grand View Research

The global monoclonal antibodies (mAbs) market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024. Increasing R&D pertaining to the development of therapeutic ...

Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2016 Market Research Report

Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Monoclonal Antibody ...

Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

  • $ 2995
  • Industry report
  • November 2016
  • by Currentpartnering

The Global Antibody Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.